AIM ImmunoTech Inc (AMEX:AIM) shares, rose in value, with the stock price up by 6.56% to the previous day’s close as strong demand from buyers drove the stock to $0.13.
Actively observing the price movement in the last trading, the stock closed the session at $0.12. Referring to stock’s 52-week performance, its high was $0.62, and the low was $0.11. On the whole, AIM has fluctuated by -29.15% over the past month.
With the market capitalization of AIM ImmunoTech Inc currently standing at about $9.04 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 200k, with a low estimate of 100k and a high estimate of 100k. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 100k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AIM’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of AIM currently trading nearly -3.87% and -26.46% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.19, while the 7-day volatility ratio is showing 15.30% which for the 30-day chart, stands at 15.31%. Furthermore, AIM ImmunoTech Inc (AIM)’s beta value is 0.77, and its average true range (ATR) is 0.02.
A comparison of AIM ImmunoTech Inc (AIM) with its peers suggests the former has fared considerably weaker in the market. AIM showed an intraday change of 6.56% in last session, and over the past year, it shrunk by -67.17%%.
Data on historical trading for AIM ImmunoTech Inc (AMEX:AIM) indicates that the trading volumes over the past 3 months, they’ve averaged 1.04 million. According to company’s latest data on outstanding shares, there are 68.75 million shares outstanding.
Nearly 11.41% of AIM ImmunoTech Inc’s shares belong to company insiders and institutional investors own 6.76% of the company’s shares. The stock has fallen by -33.59% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AIM stock heading into the next quarter.
